KRAS and non-small cell lung carcinoma: Recently, several molecular characteristics of NSCLC, including p53 mutations, epidermal growth factor receptor (EGFR) mutations with subsequent dysregulation of the ras/raf kinase pathway and k-ras mutations, have been defined [3], leading to some targeted therapy approaches.